News
- All
- Press Releases
EmerRx Biopharma Receives IRB Approval to Initiate Healthy-Volunteer PK Study of Intranasal Naloxone (EMRX-101)
Randomized crossover study in healthy adults will compare EMRX-101 to the listed 4 mg intranasal naloxone product Alameda, Calif. – November 27, 2025 – EmerRx Biopharma, LLC today announced Institutional Review Board (Advarra) approval to initiate a healthy-volunteer pharmacokinetic (PK) study of EMRX-101, the company’s improved intranasal naloxone (4 mg). The randomized crossover study will…
Press Release: EmerRx Biopharma, LLC to Present at the LD Micro Main Event XIX
Alameda, California–(Newsfile Corp. – October 6, 2025) – EmerRx Biopharma, LLC, is a biotechnology company developing next-generation intranasal drug-device combinations that deliver the speed and efficacy of intravenous administration — without the needle., announced today that it will be presenting at the 19th annual Main Event on Tuesday, October 21st at PT at the Hotel del…
Press Release: EmerRx Biopharma Announces Reg. CF Private Placement Offering
Alameda, CA – September 26, 2025 – EmerRx Biopharma is pleased to announce the launch of a private placement offering in accordance with Regulation Crowdfunding (Reg. CF) adopted by the U.S. Securities and Exchange Commission (SEC) through MicroVentures. More information on this offering can be found at: https://invest.microventures.com/offerings/emerrx. “We’re incredibly excited about this new chapter,”…
